Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0014070 (
encephalomyelitis
)
13,017
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A single injection of complete Freund's adjuvant blended with aluminum hydroxide gel (ALU-
CFA
) was successfully used to prevent clinical as well as histologic experimental allergic
encephalomyelitis
(EAE) in Lewis rats for more than 330 days. Adjuvant preparations with Mycobacterium tuberculosis were more potent than those with Mycobacterium butyricum. Neither the removal of the ALU-
CFA
inoculum nor a splenectomy 1 month after immunization arrested the adjuvant induced unresponsiveness. However cyclophosphamide restored responsiveness in more than half of the treated animals when applied 2 days before the encephalitogenic challenge at a dose of 20 mg/kg. Passive EAE was not prevented by the ALU-
CFA
pretreatment. The disease was induced by the transfer of 4 X 10(6) T lymphocytes of a cell line reactive against myelin basic protein. This indicates that the adjuvant prevents EAE at the inductive rather than at the effector phase of the autoimmune response.
...
PMID:Unresponsiveness to experimental allergic encephalomyelitis in Lewis rats pretreated with complete Freund's adjuvant. 257 28
Previous work from this laboratory has revealed that spleen and/or lymph node cells from Lewis rats, that have recovered from an acute episode of experimental autoimmune
encephalomyelitis
(EAE), suppress the development of EAE when injected into syngeneic recipients subsequently challenged with myelin basic protein (MBP) in
CFA
. In an effort to understand the mechanism of this suppression, we measured the production of immune IFN-gamma, which may be required for the induction of an immune response, by EAE effector T cells (which transfer disease) and EAE suppressor cells when cultured in vitro with MBP. We now report that EAE effector T cells produce IFN-gamma when cultured in vitro with MBP. In contrast, spleen cells from recovered rats (which manifest suppressor activity in vivo) do not produce IFN-gamma. Moreover, in cell mixing experiments, these suppressor spleen cells inhibited the production of IFN-gamma by EAE effector cells. This inhibition was not eliminated by the removal of macrophages nor by the inhibition of PG synthesis by indomethacin. Furthermore, the inhibition was shown to be Ag-specific and mediated by nylon-adherent, radiation-sensitive splenic T cells. The findings suggest that suppressor cells regulate EAE by inhibiting IFN-gamma production by effector cells. This inhibition may result in the down-regulation of IFN-gamma-induced expression of class II major histocompatibility Ag on cells of the central nervous system, thus reducing the presentation of tissue-specific Ag (i.e., MBP) to autoreactive lymphocytes.
...
PMID:Antigen-specific inhibition of immune interferon production by suppressor cells of autoimmune encephalomyelitis. 296 60
Experimental allergic
encephalomyelitis
(EAE) was induced in chickens by injecting human myelin basic protein (MBP) in Freund's complete adjuvant (
CFA
). Antibodies of IgM, IgA and IgG class to MBP were measured by enzyme-linked immunosorbent assay (ELISA). The ability of the blood from the experimental chickens to induce graft-versus-host (GvH) reaction was tested in chick embryos. Serum concentrations of sialic acid and antitrypsin were monitored. Substantial inflammatory infiltrations were found in various parts of the central nervous system of the animals injected with MBP, but not in the controls receiving plain
CFA
. Enlargement of the white pulp and plasmocytosis were found in the spleens of the EAE animals. In the course of the disease, anti-MBP IgM and IgA antibody levels strongly increased, while IgG antibodies remained unchanged. The GvH caused by the blood from EAE animals did not differ from that of control birds. The EAE group showed significantly higher antitrypsin concentration than the controls. The increase in sialic acid concentration was of equal magnitude in the EAE animals and in the
CFA
controls.
...
PMID:Experimental allergic encephalomyelitis in the chicken. Class-specific antibody to myelin basic protein, the ability of T cells to cause GvH reaction, brain and spleen histology, and nonspecific biochemical indicators of inflammation. 608 12
Experimental allergic
encephalomyelitis
(EAE) is an autoimmune disease of the central nervous system (CNS). Studies have shown that the encephalitogen responsible for EAE is the basic protein (BP) found inCNS myelin and is, perhaps, the only encephalitogenic component of the CNS. Purified lipophilin, a hydrophobic lipoprotein of myelin, was tested for its ability to induce EAE in guinea pigs. Animals challenged with myelin lipophilin (in
CFA
) developed clinical and histological signs of EAE which were indistinguishable from those developed by animals challenged with myelin BP (in
CFA
). Both lipophilin and BP induced and elicited delayed type hypersensitivity in animals challenged with either antigen and the development of delayed type hypersensitivity correlated with eventual onset of clinical signs of disease. The absence of BP from the lipophilin preparation used in this study was documented by several purification procedures and chemical modification of tryptophan in lipophilin, destroyed its ability to induce EAE. These results demonstrate that myelin lipophilin is encephalitogenic and induces a cell-mediated immune disease of the CNS similar, if not identical, to BP-induced EAE. Tryptophan, which is known to be an essential residue in the BP-determinant for disease in guinea pigs, is required for the encephalitogenic activity of lipophilin.
...
PMID:Myelin lipophilin-induced experimental allergic encephalomyelitis in guinea pigs. 615 58
Thoracic duct lymphocytes (TDL) from Lewis rats immunized 9-10 days previously with basic protein in complete Freund's adjuvant (BP-CFA) failed to induce experimental allergic
encephalomyelitis
(EAE) in syngeneic recipients. This contrasts with the successful transfer of EAE by lymph node cell suspensions from donors immunized 9 days previously with BP-
CFA
. Only minor EAE was induced passively by TDL from rats immunized 11-12 days before with BP-
CFA
. TDL collected 9-20 days after BP-
CFA
immunization, however, were successful in transferring specific suppression of EAE tested by the lack of disease in the recipients immunized actively with BP-
CFA
1 week after the TDL transfer. The data indicate that the thoracic duct contains specific suppressor cells shortly before, during and after the development of clinical EAE.
...
PMID:Suppression of experimental allergic encephalomyelitis with thoracic duct lymphocytes. 615 82
Myelin basic protein (BP) emulsified in incomplete Freund's adjuvant (BP/IFA) is relatively nonencephalitogenic in Lewis rats. Furthermore, repeated injections of BP/IFA prevent subsequent induction of experimental allergic
encephalomyelitis
(EAE) by BP emulsified in complete Freund's adjuvant (BP/
CFA
). In spite of this, spleen cells from rats injected repeatedly with BP/IFA transfer EAE after they are cultured with BP almost as effectively as BP/
CFA
spleen cells. However, unlike the latter, BP/IFA spleen cells do not proliferate in response to BP in culture. Furthermore, BP/IFA spleen cells are unable to transfer EAE after culture with concanavalin A (Con A), in contrast to BP/
CFA
spleen cells. Both populations of spleen cells undergo a strong proliferative response to Con A in culture. For BP/IFA cells, at least, a proliferative response to BP in vitro is not a prerequisite for enhanced transfer of EAE in Lewis rats.
...
PMID:Transfer of allergic encephalomyelitis with spleen cells from donors sensitized with myelin basic protein in incomplete Freund's adjuvant. 617 17
The timing and intensity of the antibody responses to the marker determinants of synthetic peptide S81 and S82 sequences of bovine myelin basic protein (MBP) (residues 68-83 and 65-83, respectively) were studied in 20 Lewis rats and 6 rabbits. All rats immunized with either peptide in
CFA
responded with antibody development. All rabbits immunized with S82 and
CFA
developed both antibodies and experimental allergic
encephalomyelitis
. In contrast only one rabbit developed antibodies against S81 and none of the S81-challenged rabbits developed disease. On the basis of extrapolation of linear time-response curves to zero activity, the time of appearance of anti-peptide antibody activity in the Lewis rats was 15.1 +/- 1.7 days after a single immunization, a week longer than the normal latent period before appearance of anti-MBP antibodies. The time of appearance of anti-S82 antibody activity in rabbits exhibiting linear response curves was 18 days, 4 days after a booster immunization with S82 in incomplete Freund's adjuvant. The development of clinical signs of experimental allergic
encephalomyelitis
occurred within 4 weeks after initial challenge (a few days after boosting) and continued for 8--13 days in all S82-immunized rabbits.
...
PMID:Immunogenicity of synthetic peptide sequences S81 and S82 (residues 68-83 and 65-83) of bovine myelin basic protein. Time-course of antibody responses in rats and rabbits. 617 60
Stimulated peritoneal exudate cells (PEC) containing activated macrophages (M phi) of Lewis (Le) rats were exposed for 1 hr in vivo or in vitro to radioiodinated soluble myelin basic protein (MBP) or MBP incorporated into magnetic microspheres (MBP-microspheres). The uptake by M phi of the dose of microsphere-bound MBP averaged 6.2%, whereas the average uptake of soluble MBP was 0.17%. Naive rats were sensitized with M phi-associated MBP or M phi-associated MBP-microspheres via the hind footpads without the aid of conventional immunologic adjuvants. Draining lymph node cells (LNC) or spleen cells from sensitized rats were cultured for 3 days with guinea pig MBP (GPMBP) alone or in combination with concanavalin A (Con A), then injected i.v. into naive recipients. Clinical signs of experimental allergic
encephalomyelitis
(EAE) appeared 6 days after transfer of LNC or spleen cells, and typical CNS lesions were seen in recipients sacrificed 10 to 14 days after transfer. The challenge of MO-MBP-sensitized rats with MBP-
CFA
resulted in severe clinical signs of EAE marked by an accelerated onset of neurologic symptoms.
...
PMID:Role of macrophage-myelin basic protein interaction in the induction of experimental allergic encephalomyelitis in Lewis rats. 619 82
Pertussigen, one of the biologically active proteins from Bordetella pertussis, was found highly active as an adjuvant to promote the induction of experimental allergic
encephalomyelitis
(EAE) in (SJL X BALB/c)F1 mice that had received at the same time an injection of mouse spinal cord (MSC) homogenized in complete Freund's adjuvant containing 4 mg of Mycobacterium tuberculosis H37RA per milliliter (CFA-H37). In this system 2 mg of MSC induced EAE, but a dose of 4 mg was more effective. As little as 250 ng of pertussigen facilitated induction of EAE, and 400 ng uniformly did so. Pertussigen was most effective when given iv from 1 day before to 5 days after administration of MSC homogenized in
CFA
-H37, when a uniform and severe disease was induced 11-13 days after immunization. Pertussigen given as late as 20 days after MSC-
CFA
-H37 still precipitated a mild form of EAE which appeared 8-12 days after the injection of pertussigen. When pertussigen was given 5 days after immunization, a chronic, nonfatal type of EAE was induced, and this persisted for the entire 74 days of observation. Histologic findings in the brain and spinal cord 15 days after sensitization in mice which received pertussigen and developed EAE showed perivascular infiltrates consisting mainly of mononuclear cells.
...
PMID:Elicitation of experimental allergic encephalomyelitis (EAE) in mice with the aid of pertussigen. 660 26
Sera from guinea pigs with acute or chronic relapsing experimental allergic
encephalomyelitis
(EAE) were injected into lumbosacral subarachnoid space of normal recipient rats. Seventeen of 37 sera induced demyelination in the CNS, and 27 of 37 sera caused demyelinated peripheral nerve fibers in the roots. The highest incidence of demyelinating activity of EAE sera was noted in those from donor animals sampled during the early chronic stage of the disease [40--100 days post sensitization (dps)]. Only few sera from animals sampled during the acute and subacute stage (10--40 dps) were able to induce demyelination. Sera from animals sampled between 100 and 200 dps showed a lower incidence of demyelinating activity as compared to those from the early chronic phase of the disease. There was no clear-cut correlation between the serum-demyelinating activity and the severity of the demyelinating disease in the donor animals. The patterns of demyelination in the central as well as peripheral nervous system of recipient animals were characterized by vesicular disruption of myelin or myelin stripping. Myelin degradation was performed mainly be macrophages. In the CNS some astrocytes also contained debris. Astrocytes increased in size, and mitosis of astrocytes was observed. Oligodendrocytes appeared to be unaffected. No demyelination was found when the sera from animals sensitized with
CFA
alone or with guinea pig liver tissue were injected into the subarachnoid space of normal recipient rats. Two possible mechanisms of demyelination are discussed: Antibody-mediated complement-dependent and antibody-dependent cell-mediated demyelination.
...
PMID:In vivo effect of sera from animals with chronic relapsing experimental allergic encephalomyelitis on central and peripheral myelin. 733 70
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>